Ligand Pharmaceuticals
LGND
330 hedge funds and large institutions have $3.26B invested in Ligand Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 119 increasing their positions, 124 reducing their positions, and 71 closing their positions.
4% less repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 124
4.35% less ownership
Funds ownership: 126.44% → 122.09% (-4.4%)
9% less funds holding
Funds holding: 362 → 330 (-32)
11% less capital invested
Capital invested by funds: $3.65B → $3.26B (-$384M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
38% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 71
49% less call options, than puts
Call options by funds: $61.7M | Put options by funds: $122M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$48.1M |
| 2 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$45.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$34.7M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$22.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$65.4M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$43.2M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$42M |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$33.6M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$29.8M |
LGND Hedge Fund Activity: Q1 2019 in Review
330 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2019, worth a combined $3.26B — down 11% from $3.65B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of LGND and 44 opened new positions — a net loss of 27 holders — while 124 trimmed existing stakes and 119 added.
The largest buyer was Janus Henderson Group, adding an estimated $48.1M. The largest seller was Millennium Management, cutting an estimated $65.4M.
- 330 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2019, down from 362 in Q4 2018.
- Funds reported $3.26B of Ligand Pharmaceuticals stock for Q1 2019, down 11% quarter-over-quarter.
- 44 funds opened new Ligand Pharmaceuticals positions in Q1 2019 and 71 closed out, a net change of -27 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2019 was Janus Henderson Group, an estimated $48.1M added.
- The largest Ligand Pharmaceuticals seller in Q1 2019 was Millennium Management, an estimated $65.4M sold.
Based on aggregated 13F filings for Q1 2019.